

The power of a unified global network

Participants to patients, one global partner

Nucleus Network in numbers

Nucleus Network is the only Phase 1 clinical research provider in the world to have clinical pharmacology units located in Australia, USA and UK. We accelerate sponsors' expansion into global top-tier markets and reduce bureaucratic hurdles.



Over 2,500
Phase 1 clinical trials conducted.



30+ years' experience
conducting Phase 1 clinical trials.



Over 300 Phase 1 clinical trial beds.



300+ sponsor audits, including FDA, MHRA and EMA regulatory inspections.



Access to 11.9 million total population across Melbourne and Brisbane (Australia).



Access to 5.7 million total population across Minneapolis-Saint Paul (USA).



Access to 8.9 million total population across London (UK).

Our expertise. Your project.

Global network

A unified global network with one purpose, to move new therapies to patients faster. Our presence across Australia, the USA and the UK gives sponsors flexibility in trial location and the clinical and regulatory expertise to choose the most efficient path forward.

Multi-country

Our sites in Melbourne, Brisbane, Minneapolis and London, and the upcoming Sydney location (opening in 2026), are strategically located within specialist hospital, research and biotech hubs. These locations offer unique access to specialised ancillary services essential for conducting a wide range of early phase clinical trials, simple to highly complex.

Strategic locations

As the largest early phase provider globally, and the largest Phase 1 provider in Australia, our footprint across Australia, the USA and the UK delivers a practical commercial advantage for sponsors. Studies begin where they will progress fastest, then continue into new areas without switching providers, systems or oversight. One global team. One quality framework. Fewer handoffs. Fewer delays. Clinical development moves with purpose, supported by one provider from region to region.



Selecting your trial site

n

Enabled by our multi-country advantage, Nucleus Network is a leader in clinical pharmacology trials, accelerating progress with multi-site capabilities that deliver high-quality data across Australia, USA and UK.

Australia

Flexible regulations and rapid clinical trial start-up in Australia help accelerate clinical timelines to achieve milestones. With sites in Melbourne and Brisbane, capacity will expand in 2026 with a new Sydney location.



176 beds



13.25 million population
(Brisbane & Melbourne)

Specialisation

- First-in-human (healthy & patient)
- Biosimilar
- Vaccine
- Drug-drug interaction (DDI)
- Food effect (Melbourne only)
- Ethnopharmacology (Bridging Studies)
- TQT

Minneapolis, USA

A premier hub for clinical development, attracting a substantial share of global pharma and biotech sponsors.



54 beds



5.7 million Minneapolis-Saint Paul population

Specialisation

- First-in-human (healthy & patient)
- Biosimilar
- Vaccine
- Drug-drug interaction (DDI)
- Complex Clinical Pharmacology
- Renal & Hepatic impairment
- TQT
- POC

London, UK

Strategically located in a global research hub with deep access to diverse and inclusive volunteer and patient populations.



145 beds



5.7 million London population

Specialisation

- First in human (healthy & patient)
- Psychedelics
- Biosimilar
- Vaccine
- Drug-Drug Interaction (DDI)
- Food Effect
- Ethnopharmacology (Bridging Studies)
- TQT



Strategic locations

With sites across Melbourne, Brisbane, Minneapolis, and soon Sydney (2026), we offer unmatched reach, expertise and purpose-built trial acceleration.



Brisbane, AUS

Australia's second largest Phase I clinical trial facility and the ONLY Phase 1 unit dedicated to early clinical development of New Biological Entities (NBE's), Biosimilars and Vaccines.


- Centre of Excellence for biosimilars and vaccines
- Capacity: 61 beds
- Co-located with Royal Brisbane & Women's Hospital (900-bed)



Melbourne, AUS

Our Melbourne facility is Australia's largest and most experienced Phase 1 unit and a global leader in first-in-human trials.

- Largest early-phase unit in Australia
- Capacity: 110 beds
- Specialist FIH and clinical pharmacology site
- Co-located with The Alfred Hospital (800-bed tertiary facility)



Minneapolis, US

Co-located within University Enterprise Labs, within the Medical Alley Precinct.

- US flagship site with onsite dialysis capabilities
- Capacity: 54 beds
- Specialisation in renal, hepatic and complex pharmacology
- Located in the Medical Alley region



London, UK

Purpose-built unit in north-west London near Central Middlesex Hospital, specialising in early-phase trials with large inpatient capacity, complex designs and hospital-grade services.

- Full service for Phase 1 and early Phase 2 trials
- Capacity: 145 beds
- Highly automated on-site laboratory, with rapid turnaround



Key therapeutic areas

Known for delivering highly complex first in human studies in a range of therapeutic areas, our vast access to highly specialised services and procedural capabilities are unmatched globally.

We have well-established relationships with hospital and research facilities, and our co-location with health and medical precincts at each of our sites enables us to access a range of Key Opinion Leaders and ancillary services. This enhances our offering to our sponsors when designing and executing clinical trials and includes access to patients and complex specialised assessments.



Cardiology

- TTE/TEE
- Telemetry
- Holter monitoring
- Exercise/Nuclear Stress Test
- Advanced Rhythm Analysis



Dermatology

- Punch Biopsies
- Skin irritation assessment
- PASI scoring



Gastroenterology

- Fibro scan
- Sigmoidoscopy
- Endoscopy
- Liver ultrasound
- MRI liver fat



Immunology

- Gluten challenge
- Nasal challenge
- Skin prick allergy test



Infectious diseases

- Group A Streptococcus challenge model
- Malaria challenge model



Metabolism & Endocrinology

- Metabolic Calorimeter
- DEXA imaging
- Glucose clamping
- Glucose tolerance test
- Mixed meal tolerance test
- MRI PDFF



Neurology

- Lumbar puncture
- EEG
- Cogstate battery
- Pain & Therstimulatory



Ophthalmology

- Tonometry
- Dark adaptometry
- BCVA-ETDRS
- FAF
- Bimicroscopy
- Fundus Exam
- OCT & ERG



Radiology

- CT imaging
- PET imaging
- X-Ray
- Ultrasound
- MRI



Respiratory

- Bronchoalveolar lavage (BAL)
- Spirometry (FEV1, FVC)
- NO2 assay



Women's Health

- Colposcopy
- PAP Smears

Contact Nucleus Network



partnering@nucleusnetwork.com



nucleusnetwork.com/sponsors



Advancing medicine, improving lives.